1-7 of 7
Aramesh Saremi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

Glycemic Target Attainment in Insulin-Naïve Patients with T2D Receiving iGlarLixi

CYRUS DESOUZA, VIVIAN FONSECA, JUAN P. FRIAS, LUC VAN GAAL, FRANCESCO GIORGINO, JASON CHAO, TERRY A. DEX, MICHELLE ROBERTS, ARAMESH SAREMI, LAWRENCE A. LEITER
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1093-P
https://doi.org/10.2337/db18-1093-P
Published: 01 July 2018
View article titled, Glycemic Target Attainment in Insulin-Naïve Patients with T2D Receiving iGlarLixi
Meeting Abstracts

Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. IGlar—A Subanalysis of LixiLan-L

LAWRENCE BLONDE, LORI BERARD, ARAMESH SAREMI, YAO HUANG, VANITA ARODA, DENIS RACCAH
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1094-P
https://doi.org/10.2337/db18-1094-P
Published: 01 July 2018
View article titled, Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. IGlar—A Subanalysis of LixiLan-L
Meeting Abstracts

iGlarLixi Effectively Reduces Residual Hyperglycemia in Patients with Type 2 Diabetes on Basal Insulin—A Post-Hoc Analysis from the LixiLan-L Study

FRANCESCO GIORGINO, RAVI RETNAKARAN, JOSEP VIDAL, VANITA ARODA, ARAMESH SAREMI, MINZHI LIU
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1095-P
https://doi.org/10.2337/db18-1095-P
Published: 01 July 2018
View article titled, iGlarLixi Effectively Reduces Residual Hyperglycemia in Patients with Type 2 Diabetes on Basal Insulin—A Post-Hoc Analysis from the LixiLan-L Study
Meeting Abstracts

A1C Target Attainment in Patients with T2D Receiving iGlarLixi Who Reach PPG and FPG Targets in the Lixilan-L Trial

LAWRENCE A. LEITER, JASON CHAO, ARAMESH SAREMI, TERRY A. DEX, JAIME A. DAVIDSON, IV
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1089-P
https://doi.org/10.2337/db18-1089-P
Published: 01 July 2018
View article titled, A1C Target Attainment in Patients with T2D Receiving iGlarLixi Who Reach PPG and FPG Targets in the Lixilan-L Trial
Meeting Abstracts

Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes

PABLO MORA, JASON CHAO, ARAMESH SAREMI, TERRY A DEX, MICHELLE ROBERTS, GUILLERMO E UMPIERREZ
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1072-P
https://doi.org/10.2337/db18-1072-P
Published: 01 July 2018
View article titled, Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes
Meeting Abstracts

Lixisenatide and Renal Outcomes in Patients with Type 2 Diabetes—A Post-Hoc Analysis of the ELIXA Trial

MARCEL A. MUSKIET, LENNART TONNEIJCK, YAO HUANG, MINZHI LIU, ARAMESH SAREMI, HIDDO LAMBERS. HEERSPINK, DANIËL H. VAN RAALTE
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1060-P
https://doi.org/10.2337/db18-1060-P
Published: 01 July 2018
View article titled, Lixisenatide and Renal Outcomes in Patients with Type 2 Diabetes—A Post-Hoc Analysis of the ELIXA Trial
Journal Articles

High Alanine Aminotransferase Is Associated With Decreased Hepatic Insulin Sensitivity and Predicts the Development of Type 2 Diabetes

Barbora Vozarova, Norbert Stefan, Robert S. Lindsay, Aramesh Saremi, Richard E. Pratley, Clifton Bogardus, P. Antonio Tataranni
Journal: Diabetes
Diabetes 2002;51(6):1889–1895
https://doi.org/10.2337/diabetes.51.6.1889
Published: 01 June 2002
View article titled, High Alanine Aminotransferase Is Associated With Decreased Hepatic Insulin Sensitivity and Predicts the Development of Type 2 Diabetes
Open the PDF for High Alanine Aminotransferase Is Associated With Decreased Hepatic Insulin Sensitivity and Predicts the Development of Type 2 Diabetes in another window